• LAST PRICE
    1.8071
  • TODAY'S CHANGE (%)
    Trending Down-0.0529 (-2.8441%)
  • Bid / Lots
    1.7700/ 9
  • Ask / Lots
    1.9000/ 10
  • Open / Previous Close
    1.8506 / 1.8600
  • Day Range
    Low 1.8001
    High 1.8530
  • 52 Week Range
    Low 1.2150
    High 13.3750
  • Volume
    7,322
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 1.86
TimeVolumeNBRV
09:32 ET2801.8506
10:54 ET7091.853
11:05 ET3001.83
11:45 ET1301.8299
11:57 ET2001.802
12:06 ET12101.8072
12:08 ET1001.8332
12:10 ET1091.8266
12:32 ET1101.83
12:48 ET1111.8523
02:25 ET2191.815
02:32 ET1111.8244
02:34 ET1001.829
02:38 ET1001.83
02:39 ET4001.84
03:12 ET2001.81
03:26 ET2001.8001
03:30 ET4001.8134
03:55 ET2501.8071
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNBRV
Nabriva Therapeutics PLC
5.7M
-0.1x
---
United StatesANGN
Angion Biomedica Corp
20.9M
-1.2x
---
United StatesPRED
Predictive Technology Group Inc
89.9K
0.0x
---
United StatesSQZ
SQZ Biotechnologies Co
24.4M
-0.3x
---
United StatesCASI
CASI Pharmaceuticals Inc
27.2M
-1.0x
---
United StatesVDRM
Viaderma Inc
5.5M
0.0x
---
As of 2023-02-08

Company Information

Nabriva Therapeutics plc is a biopharmaceutical company. The Company is engaged in the commercialization and research and development of anti-infective agents to treat serious infections. Its products include SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO. SIVEXTRO product is an oxazolidinone class antibiotic to treat susceptible Gram-positive pathogens, including methicillin-resistant staphylococcus aureus (MRSA). XENLETA product is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death. CONTEPO is an investigational IV antibiotic in the United States with a spectrum of Gram-negative and Gram-positive activity, including activity against MDR strains, such as extended-spectrum β-lactamase-, or ESBL-producing Enterobacteriaceae.

Contact Information

Headquarters
Alexandra House Office 225/227 , The Sweepstakes,, BallsbridgeDUBLIN, Ireland D01 H104
Phone
610-816-6640
Fax
---

Executives

Independent Chairman of the Board
Daniel Burgess
Interim Chief Executive Officer, General Counsel, Secretary
J. Christopher Naftzger
Chief Financial Officer
Daniel Dolan
Chief Medical Officer
Christine Guico-Pabia
Director
Colin Broom

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.7M
Revenue (TTM)
$35.6M
Shares Outstanding
3.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.60
EPS
$-19.49
Book Value
$23.52
P/E Ratio
-0.1x
Price/Sales (TTM)
0.2
Price/Cash Flow (TTM)
---
Operating Margin
-129.24%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.